Thursday, October 16, 2014

Dr. Joseph Brewer at ILADS, 2014

ILADS is a professional scientific conference focusing on the education and treatment of Lyme disease and its co-infections. This year's conference in Washington DC was packed.

I was particularly pleased to see Dr. Neil Nathan from Gordon Medical Associates give several lectures, one on viral treatment for the Lyme patient and one on methylation. Dr. Nathan is a remarkable clinician, one who is open to suggestion regarding different treatment modalities. Dr. Nathan, Dr. Eric Gordon and Dr. Wayne Anderson form a unique group of physicians working on these complex illnesses out of one clinic, Gordon Medical Associates in Santa Rosa, CA. 

Dr. Nathan worked closely with Rich van Konynenburg. In 2009, they did an important study together on methylation.

I really went to ILADS to hear Dr. Joseph Brewer update us on his treatment for Mycotoxins in ME/CFS and Lyme. The bottom line of Dr. Brewer’s lecture was that this treatment is continuing to provide remarkable results. Over time Dr. Brewer has gained confidence that he is really onto something here. Many others are beginning also to understand and treat patients for mold and mycotoxin involvement.

A previous blog post from October 2013 covered Dr. Brewers previous Mycotoxins lecture at ILADS. It can be found here.

Once again Dr. Brewer gave a quick review of the overall picture of mycotoxins and chronic illness.  Dr. Brewer pointed out that mycotoxins suppress all aspects of the immune system. Certainly this is what Shoemaker and others have found. 

Dr. Brewer continues to use Ampho B in an atomized nasal application. Ampho B has caused serious nasal irritation in some patients. These patients either cut back their treatment or shift to another treatment drug.

Dr. Brewer presented a pilot study, done with his own patients. This is an open label observational study done by him and his patients. This pilot study covered treatment of 151 patients between May 2013 and May 2014. The treatment for all patients was two fold: nasal atomized Ampho B and nasal atomized PX chelating formula. Chelating PX is a combination of EDTA and a surfactant. Each patient did each agent once daily for at least six months. A few were every other day dosage.

56 patients dropped out, not able to tolerate Ampho B.

94 of 151 continued on the study. 

Of those 94, 88 showed improvement at the end of the study. This is a 93.7% improvement rate. Improvement was 25-50% or greater from baseline, and this was self-reported.

One third of the 88 are pretty much back to normal. These patients have had a complete resolution of symptoms. 

58% of the total 151 improved with this treatment. 

Die off was reported at 13%. Dr. Brewer believes the die off percentage was higher, perhaps in range of 30-40%.

22 patients continue to be followed. Some of these have stopped treatment while others were on maintenance doses. A number of patients have relapsed after stopping treatment.

A few patients, more recently, have stayed off treatment and have not regressed. It is believed that the treatment has to be continued for a certain unspecified duration for complete resolution.

Since April 2014, Dr. Brewer has begun using nasal Nystatin on a number of his newer patients. He has now treated 80 patients with Nystatin. Most of them were in the Ampho B intolerant group. ASL pharmacy has been unsuccessful in making a liquid formulation of Nystatin for atomization. Instead they fashioned it in a pill form. The pill is opened and the powdered Nystatin is mixed with distilled water prior to being atomized with the Nasa-Touch. The patients on Nystatin have no nasal symptoms. It seems to be very user friendly on the nose. Die off is about the same as with Ampho B cohort. Preliminary results indicate that these patients are improving on nasal Nystatin treatment.

There may be other agents that could be useful and they will be studied.

This report is for informational and educational purposes only. It is not to be seen as medical advice in any way.